Naloxone challenge in smokers: Preliminary evidence of an opioid component in nicotine dependence

Archives of General Psychiatry

Volumn 56, Issue 7, 1999, Pages 663-668

  Krishnan Sarin, Suchitra ^a,b   Rosen, Marc I ^c   O'Malley, Stephanie S ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Substance Abuse Treatment Unit   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIGARETTE SMOKE; HYDROCORTISONE; NALOXONE; NICOTINE; OPIATE ANTAGONIST; OPIATE RECEPTOR;

ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; SMOKING CESSATION; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

EID: 0032976061     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.56.7.663     Document Type: Article

References (47)

1. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Washington, DC: Dept of Health and Human Services; 1988:145-240. DHHS Publication 88-8406.
2. Margioris AN, Markogiannakis E, Makeigiannakis A, Gravanis A. PC-12 rat pheochromocytoma cells synthesize dynorphin; its secretion is modulated by nicotine and nerve growth factor. Endocrinology. 1992;131:703-709.
3. Houdi AA, Pierzchala K, Marson L, Palkovits M, Van Loon GR. Nicotine induced alteration in Tyr-Gly-Gly and metenkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptide. 1991;12:161-166.
4. Pierzchala K, Houdi AA, Van Loon GR. Nicotine-induced alterations in brain regional concentrations of native and cryptic Met- and Leu-enkephalin. Peptide. 1987;8:1035-1043.
5. Pomerleau OF, Fertig JB, Everett-Seyler L, Jaffe J. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology. 1983;81:61-67.
6. Clarke PBS, Pert CB, Pert A. Autoradiographic distribution of nicotine receptors in rat brain. Brain Res. 1984;323:390-395.
7. Palkovits M. Neuropeptides in the brain. In: Martini L, Ganong WF, eds. Frontiers in Neuroendocrinology. New York, NY: Raven Press; 1988:1-140.
8. Hollt V, Horn G. Effect of nicotine on mRNA levels encoding opioid peptides, vasopressin and alpha3 nicotinic receptor subunit in the rat. Clin Invest. 1991;70: 224-231.
9. Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, Carter VA, Cunningham JS, Wilson OB. A rodent model of nicotine abstinence. Pharmacol Biochem Behav. 1992;443:179-184.
10. Malin DH, Lake RL, Carter VA, Cunningham JS, Wilson OB. Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology. 1993;112: 339-342.
11. Rosecrans JA, Hendry JS, Hong J-S. Biphasic effects ot chronic nicotine treatment on hypothalamic immunoreactive β-endorphin in the mouse. Pharmacol Biochem Behav. 1985;23:141-143.
12. Jaffe JH, Martin WR. In: Gillman AG, ed. Pharmacological Basis of Therapeutics. 7th ed. New York, NY: Macmillan Publishing Co Inc; 1985:491-531.
13. Peachey JE, Lei H. Assessment of opiate dependence with naloxone. Br J Addict. 1988;83:193-201.
14. Rosen MI, McMahon TJ, Margolin A, Gill TS, Woods SW, Pearsall HR, Kreek MJ, Kosten TR. Reliability of sequential naloxone challenge tests. Am J Drug Alcohol Abuse. 1995;21:453-457.
15. Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-III-R, Patient Version. New York: New York State Psychiatric Institute; 1995.
16. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86:1119-1127.
17. Fishman J, Roffwarg H, Hellman L. Disposition of naloxone-7,8,3H in normal and narcotic-dependent men. J Pharmacol Exp Ther. 1973;187:575-80.
18. Berkowitz BA, Ngai SH, Hempstead J, Spector S. Disposition of naloxone: use of a new radioimmunoassay. J Pharmacol Exp Ther. 1975;195:499-504.
19. Tiffany ST, Drobes DJ. The development and initial validation of a questionnaire on smoking urges. Br J Addict. 1991;86:1467-1476.
20. Burton P, Gurrin L, Sly P. Extending the simple linear regression model to account for correlated responses: an introduction to generalized estimating equations and multi-level mixed modeling. Stat Med. 1998;17:1261-1291.
21. Smith F. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients. J Biopharmacol Stat. 1996;6:59-67.
22. Sutherland G, Stapleton JA, Russell MAH, Feyerband C. Naltrexone, smoking behavior and cigarette withdrawal. Psychopharmacology. 1995;120:418-425.
23. Gorelick DA, Rose J, Jarvik ME. Effect of naloxone on cigarette smoking. J Subst Abuse. 1989;1:153-159.
24. Karras A, Kane J. Naloxone reduces cigarette smoking. Life Sci. 1980;27:1541-1545.
25. Nemeth-Coslett R, Griffiths RR. Naloxone does not affect cigarette smoking. Psychopharmacology. 1986;89:261-264.
26. Kreek MJ. Opiates, opioids and addiction. Mol Psych. 1996;1:232-254.
27. Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev. 1991;43:427-473.
28. Adinoff B, Martin PR, Bone GHA, Eckdart M, Roehrich L, George DT, Moss HB, Eskay R, Linnoila M, Gold PW. Hypothalamic-pituitary-adrenal axis functioning and cerebrospinal fluid corticotropin levels in alcoholics after recent and long-term abstinence. Arch Gen Psychiatry. 1990;47:325-330.
29. Wand GS, Dob AS. Alterations in the hypothalamic-pituitary-adrenal axis in actively drinking alcoholics. J Clin Endocrinol Metab. 1991;72:1290-1295.
30. Froehlich JC, Li RK. Opioid peptides. In: Galanter M, ed. Recent Developments in Alcoholism. New York, NY: Plenum Press; 1995:187-205.
31. Gianaloukis C, deWaele J-P. Genetics of alcoholism: role of endogenous opioid system. Metab Brain Dis. 1994;9:105-131.
32. Kemper A, Koalick F, Thiele H, Retzow A, Rathsack R, Nickel B. Cortisol and β-endorphin response in alcoholics and alcohol abusers following a high naloxone dosage. Drug Alcohol Depend. 1990;25:319-326.
33. Wand GS, Mangold D, El Deiry S, McCaul ME, Hoover D. Family history of alcoholism and hypothalamic opioidergic activity. Arch Gen Psychiatry. 1998;55: 1114-1119.
34. Kirschbaum C, Strasburger CJ, Langkrar J. Attenuated cortisol response to psychological stress but not to CRH or ergometry in young habitual smokers. Pharmacol Biochem Behav. 1993;44:527-531.
35. Caggiula AR, Donney EC, Epstein LH, Sved AF, Knopf S, Rose C, McAllister CG, Antelman SM, Perkins KA. The role of corticosteroids in nicotine's physiological and behavioral effects. Psychoneuroendocinology. 1998;23:143-159.
36. Puddey IB, Vandongen R, Beilin LJ, English D. Haemodynamic and neuroendocrine consequences of stopping smoking: a controlled study. Clin Exp Pharmacol Physiol. 1984;11:423-426.
37. Frederick SL, Reus VI, Ginsderg D, Hall SM, Munoz RF, Ellman G. Cortisol and response to dexamethasone as predictors of withdrawal distress and abstinence success in smokers. Biol Psychiatry. 1998;43:525-530.
38. Pickworth WB, Baumann MH, Fant RV, Rothman RB, Henningfield JE. Endocrine responses during acute nicotine withdrawal. Pharmacol Biochem Behav. 1996;55:433-437.
39. Cherek DR, Smith JE, Lane JD, Brauchi JT. Effect of cigarettes on saliva cortisol levels. Clin Pharmacol Ther. 1982;32:765-768.
40. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgreen LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 1986;143:993-997.
41. Glassman AH. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry. 1993;150:546-553.
42. Breslau N, Kilbey MM, Andreski P. Nicotine dependence and major depression: new evidence from a prospective investigation. Arch Gen Psychiatry. 1993;50: 31-35.
43. Hughes JR. Clinical implications of the association between smoking and alcoholism. In: Fertig JP, Allen JP, eds. Alcohol and Tobacco: From Basic Science to Clinical Practice. Washington. DC: National Institute on Alcohol Abuse and Alcoholism; 1995:
44. Stark MJ, Campbell BK. Drug use and cigarette smoking in applicants for drug abuse treatment. Subst Abuse. 1993;3:175-181.
45. Berger H, Schweigler M. Smoking characteristics of methadone patients. JAMA. 1972;222:705.
46. Burling TA, Salvio MA, Seidner AI, Ramsey TG. Cigarette smoking in alcohol and cocaine abusers. J Subst Abuse. 1996;8:445-452.
47. Wiseman EJ, McMillan DE. Combined use of cocaine with alcohol or cigarettes. Am J Drug Alcohol Abuse. 1996;22:577-587.